Table 1

Baseline characteristics of patients according to the absolute lymphocyte count at day 15 (ALC-15) after ASCT

CharacteristicsALC-15 < 500 cells/μL (n = 86)ALC-15 ≥ 500 cells/μL (n = 59)P
Age (y)
    Median (range)55 (35-69)55 (31-71)0.88
Sex
    Females32270.50
    Males5232
Prognostic factors for amyloidosis
Age (y)
    ≥5063400.58
    <502319
Albumin (g/dl)
    ≥3.520100.41
    <3.56649
Alkaline (units/L) phosphatase
    >3751770.26
    ≤3756952
β-2 microglobulin (mg/L)
    ≥2.729150.36
    <2.75744
Bone marrow plasma cells (%)
    >201550.15
    ≤207154
Circulating plasma cells (%)
    >1320.97
    ≤18357
C-reactive protein (mg/L)
    >0.81280.95
    ≤0.87451
Creatinine (mg/L)
    >2.0910.05
    ≤2.07758
Ejection fraction (%)
    ≥6066480.54
    <602611
Interventricular septal thickness (mm)
    ≥1526140.45
    <156045
LDH
    Elevated2360.02
    Normal for age/sex6353
No. organs involved
    >215110.85
    ≤27148
Plasma cell labeling index (%)
    ≥1520.70
    <18157
Serum light chain by immunofixation
    λ46310.79
    κ1311
    None2716
Serum M spike (g/dl)
    >1.01860.11
    ≤1.06853
24 h urine protein (g)
    >3.048340.87
    ≤3.03825
Troponin T* (μg/L)
    ≥0.0351240.20
    <0.0355036
Urine light chain by immunofixation
    λ57410.79
    κ2011
    None97
Urine M protein (g/d)
    >0.2531230.73
    ≤0.255536
Free κ light chain before ASCT (g/L)
    >0.02624180.80
    ≤0.026159
    >0.0191470.43
    ≤0.0192520
No. prior therapies
    058380.59
    12316
    254
    301
Stem cell mobilization regimens
    Cytoxan/GM-CSF16140.46
    G-CSF7045
Conditioning regimens
    Melphalan/TBI690.05
    Melphalan 2004638
    Melphalan 16001
    Melphalan 140289
    Melphalan 10062
  • * Only available data in 102 patients.

  • Only available data in 66 patients.